ClinicalTrials.gg
CompletedNCT03553563Updated Mar 4, 2026Results posted

A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duodenal Ulcer

A Phase 3 interventional study of D961H capsule 10mg and D961H sachet 10mg in Reflux Esophagitis, Gastric Ulcer and Duodenal Ulcer, sponsored by AstraZeneca. Completed at 15 sites in Japan. Open to participants aged 1 Year to 14 Years. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by AstraZeneca · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
1 Year to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Esophagitis, Peptic by AstraZeneca — none open to participants now, none under way, none of them phase 3. Esophagitis, Peptic · AstraZeneca.

Started
2018
the only one that year
Phase 3
5 of 12
none open now
Registered
12th of 12
by date

Among the 12 studies in Esophagitis, Peptic by AstraZeneca, this one is the only one that started in 2018, is one of 5 in phase 3, and was the 12th registered.

Esophagitis, Peptic

83 studies on the registry are indexed under Esophagitis, Peptic; 16 are open to participants now.

Browse Esophagitis, Peptic studies →

Open to participants now

None of the 12 studies in Esophagitis, Peptic by AstraZeneca is open now. The open studies under Esophagitis, Peptic, anywhere →

Where they have run

Who these studies take

Of the 8 Esophagitis, Peptic studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 1 Year to 14 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Esophagitis, Peptic by AstraZeneca as a file.
02

Study summary

This is an open label, parallel group, multi-centre, phase III study to assess the safety and efficacy of D961H in maintenance therapy following initial healing therapy in Japanese paediatric patients with reflux esophagitis, and to assess the safety and efficacy of D961H in Japanese paediatric patients treated with long term non-steroidal anti-inflammatory drugs or low-dose aspirin therapy who have a documented medical history of gastric ulcer or duodenal ulcer diagnosis.

Doses of D961H in this study is set for the 2 groups (weight more than equal 10 kg to less than 20 kg and weight more than equal 20 kg) in the maintenance therapy for healed reflux esophagitis group and the prevention of gastric ulcer or duodenal ulcer recurrence by non-steroidal anti-inflammatory drugs or low-dose aspirin therapy group, Primary endpoints are evaluated at week 32. Further, this study is designed to evaluate the long term efficacy and safety of D961H for a maximum of 52 weeks, in consideration of the medical needs for long term proton pump inhibitor treatment. Patient can continue study treatment up to 52 weeks, if they want

Read the detailed description

Subjects are allocated to four groups based on their disease and weight.

Number of Subjects

Maintenance therapy for healed reflux esophagitis study part:

  • Group1:aged 1 to 14 years (weight more than equal 10 kg to less than 20 kg ), Maintenance phase, n=5 to 10
  • Group2:aged 1 to 14 years (weight more than equal 20 kg), Maintenance phase, n=10 to 20

Prevention of gastric ulcer or duodenal ulcer recurrence associated with long term non-steroidal anti-inflammatory drugs or low-dose aspirin therapy study part:

  • Group3:aged 1 to 14 years (weight more than equal 10 kg to less than 20 kg), n=5 to 10 at Week 0
  • Group4:aged 1 to 14 years (weight more than equal 20 kg), n=10 to 20 at Week 0

All subjects have a D961H administration for 32 or 52 weeks. all esophagogastroduodenoscopy findings are reviewed by central evaluation committee and study is conducted based on the judgement of central evaluation committee.

Data are entered in electric data capture system at study site by site staffs and all data are verified with source data by site monitors during the study.

Analyses will be performed by AstraZeneca or its representatives. A comprehensive statistical analysis plan will be developed and finalised before database lock and will describe the subject populations to be included in the analyses, and procedures for accounting for missing, unused, and spurious data. This section is a summary of the planned statistical analyses of the primary and secondary endpoints. Any deviations from this plan will be reported in the clinical study report.

Efficacy analyses are intended for Efficacy Analysis Set. ・Efficacy Analysis Set:All subjects who take at least 1 dose of the investigational product and have at least 1 efficacy datum assessment during the maintenance/prevention therapy period, and who have no important protocol deviation.

All safety analyses are performed on the Safety Analysis Set.

・Safety Analysis Set:All subjects who take at least 1 dose of the investigational product and have any post-treatment assessment.

Frequency and incidence rate of adverse events (AEs), serious adverse events (SAEs), discontinuation of investigational product due to adverse events (DAEs) and other significant adverse events (OAEs) will be presented by MedDRA System Organ Class (SOC) and Preferred Term (PT) for each group. In addition, summaries of AEs will be further broken down by maximum intensity and relationship to the investigational product as assigned by investigators

03

Conditions studied

  • Reflux Esophagitis
  • Gastric Ulcer
  • Duodenal Ulcer

Keywords

  • D961H
  • paediatric
  • reflux esophagitis
  • gastric ulcer
04

Who can participate

Ages eligible
1 Year to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For healed reflux esophagitis study

  • Endoscopically verified reflux esophagitis, Grade A or higher according to the Los Angels classification as judged by central evaluation committee.

For prevention of gastric ulcer or duodenal ulcer recurrence study

  • Patients with documented medical history of gastric ulser or duodenal ulser diagnosis based on upper gastrointestinal symptoms, fecal occult blood, esophagogastroduodenoscopy findings, etc.

Exclusion criteria

Exclusion Criteria:

  • Patients less than 10 kg in weight.
  • Use of any other compounds or participations in another clinical trial within 4 weeks prior to the enrolment.
  • Significant clinical illness within 4 weeks prior to the
  • Previous total gastrectomy.
  • Presence of hepatic diseases or other conditions that could interfere with evaluation of the study as judged by investigators. etc.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Group1

    Initial healing phase (8 weeks), D961H 10 mg once-daily; Maintenance phase (24 or 44 weeks), D961H 10 mg once-daily

    Drug: D961H capsule 10mg · Drug: D961H sachet 10mg

  • Experimental
    Group2

    Initial healing phase (8 weeks), D961H 20 mg once-daily; Maintenance phase (24 or 44 weeks) starts with D961H 10 mg once-daily and may be increased to 20 mg once-daily based on investigator's discretion

    Drug: D961H capsule 10mg · Drug: D961H sachet 10mg

  • Experimental
    Group3

    D961H 10 mg once-daily (32 or 52 weeks)

    Drug: D961H capsule 10mg · Drug: D961H sachet 10mg

  • Experimental
    Group4

    D961H starts with 10 mg once-daily, and may be increased to 20 mg once-daily based on investigator's discretion (32 or 52 weeks)

    Drug: D961H capsule 10mg · Drug: D961H sachet 10mg

Interventions

  • All Groups can select either capsule or sachet during the study.

    Also known as: esomeprazole

  • All Groups can select either capsule or sachet during the study.

    Also known as: esomeprazole

06

What researchers measure

Primary outcomes

  1. Presence/Absence of Reflux Esophagitis Relapse

    Maintenance therapy for healed reflux esophagitis study part: Presence/absence of reflux esophagitis relapse from 8 to 32 weeks for all participants by assessment of the composite endpoint (reflux esophagitis -related symptoms or optional esophagogastroduodenoscopy findings) during the maintenance therapy.

    Time frame: 8 to 32 weeks

  2. Presence/Absence of Gastric Ulcer or Duodenal Ulcer Recurrence

    Prevention of gastric ulcer or duodenal ulcer recurrence associated with long term non-steroidal anti-inflammatory drugs or low-dose aspirin therapy study part: Presence/absence of gastric ulcer or duodenal ulcer recurrence from 0 to 32 weeks for all participants by assessment of the composite endpoint (gastric ulcer or duodenal ulcer-related symptoms or optional esophagogastroduodenoscopy findings) during the prevention therapy.

    Time frame: 0 to 32 weeks

  3. Adverse Events During Reflux Esophagitis Maintenance Therapy

    Maintenance therapy for healed reflux esophagitis study part: Safety from 8 to 32 weeks for all participants. Number of participants with any adverse event during the period.

    Time frame: 8 to 32 weeks

  4. Adverse Events During Gastric Ulcer or Duodenal Ulcer Recurrence Prevention Therapy

    Prevention of gastric ulcer or duodenal ulcer recurrence associated with long term non-steroidal anti-inflammatory drugs or low-dose aspirin therapy study part: Safety from 0 to 32 weeks for all participants. Number of participants with any adverse event during the period.

    Time frame: 0 to 32 weeks

Secondary outcomes

  1. Presence/Absence of Reflux Esophagitis Relapse

    Presence/absence of reflux esophagitis relapse from 8 to 52 weeks for participants who continued the study treatment after Week 32 by assessment of the composite endpoint (reflux esophagitis-related symptoms or optional esophagogastroduodenoscopy findings) during the maintenance therapy.

    Time frame: 8 to 52 weeks

  2. Presence/Absence of Gastric Ulcer or Duodenal Ulcer Recurrence

    Presence/absence of gastric ulcer or duodenal ulcer recurrence from 0 to 52 weeks for participants who continued the study treatment after Week 32 by assessment of the composite endpoint (gastric ulcer or duodenal ulcer-related symptoms or optional esophagogastroduodenoscopy findings) during the prevention therapy.

    Time frame: 0 to 52 weeks

  3. Adverse Events During Reflux Esophagitis Maintenance Therapy

    Maintenance therapy for healed reflux esophagitis study part: Safety from 8 to 52 weeks for participants who continued the study treatment after Week 32. Number of participants with any adverse event during the period

    Time frame: 8 to 52 weeks

  4. Adverse Events During Gastric Ulcer or Duodenal Ulcer Recurrence Prevention Therapy

    Prevention of gastric ulcer or duodenal ulcer recurrence associated with long term non-steroidal anti-inflammatory drugs or low-dose aspirin therapy study part: Safety from 0 to 52 weeks for participants who continued the study treatment after Week 32. Number of participants with any adverse event

    Time frame: 0 to 52 weeks

07

Results

Posted Mar 4, 2026

Participant flow

First participant enrolled on 24 July 2018 Last participant last visit on 27 December 2022. This study was conducted at a total of 17 sites in Japan.

Participant flow — Overall Study
MilestoneGroup 1Group 2Group 3Group 4
Started721913
Completed618912
Not completed1301
Withdrew: Protocol violation0100
Withdrew: Withdrawal by subject0001
Withdrew: Physician decision1100
Withdrew: Adverse event0100

Outcome measures

PrimaryPresence/Absence of Reflux Esophagitis Relapse

Maintenance therapy for healed reflux esophagitis study part: Presence/absence of reflux esophagitis relapse from 8 to 32 weeks for all participants by assessment of the composite endpoint (reflux esophagitis -related symptoms or optional esophagogastroduodenoscopy findings) during the maintenance therapy.

Time frame:
8 to 32 weeks
Reported as:
Count of participants · Participants
Presence/Absence of Reflux Esophagitis Relapse
ParticipantsGroup 1Group 2
Presence of reflux esophagitis relapse01
Absence of reflux esophagitis relapse718
PrimaryPresence/Absence of Gastric Ulcer or Duodenal Ulcer Recurrence

Prevention of gastric ulcer or duodenal ulcer recurrence associated with long term non-steroidal anti-inflammatory drugs or low-dose aspirin therapy study part: Presence/absence of gastric ulcer or duodenal ulcer recurrence from 0 to 32 weeks for all participants by assessment of the composite endpoint (gastric ulcer or duodenal ulcer-related symptoms or optional esophagogastroduodenoscopy findings) during the prevention therapy.

Time frame:
0 to 32 weeks
Reported as:
Count of participants · Participants
Presence/Absence of Gastric Ulcer or Duodenal Ulcer Recurrence
ParticipantsGroup 3Group 4
Presence of gastric ulcer or duodenal ulcer recurrence10
Absence of gastric ulcer or duodenal ulcer recurrence813
SecondaryPresence/Absence of Reflux Esophagitis Relapse

Presence/absence of reflux esophagitis relapse from 8 to 52 weeks for participants who continued the study treatment after Week 32 by assessment of the composite endpoint (reflux esophagitis-related symptoms or optional esophagogastroduodenoscopy findings) during the maintenance therapy.

Time frame:
8 to 52 weeks
Reported as:
Count of participants · Participants
Presence/Absence of Reflux Esophagitis Relapse
ParticipantsGroup 1Group 2
Presence of reflux esophagitis relapse14
Absence of reflux esophagitis relapse512
SecondaryPresence/Absence of Gastric Ulcer or Duodenal Ulcer Recurrence

Presence/absence of gastric ulcer or duodenal ulcer recurrence from 0 to 52 weeks for participants who continued the study treatment after Week 32 by assessment of the composite endpoint (gastric ulcer or duodenal ulcer-related symptoms or optional esophagogastroduodenoscopy findings) during the prevention therapy.

Time frame:
0 to 52 weeks
Reported as:
Count of participants · Participants
Presence/Absence of Gastric Ulcer or Duodenal Ulcer Recurrence
ParticipantsGroup 3Group 4
Presence of gastric ulcer or duodenal ulcer recurrence10
Absence of gastric ulcer or duodenal ulcer recurrence57
PrimaryAdverse Events During Reflux Esophagitis Maintenance Therapy

Maintenance therapy for healed reflux esophagitis study part: Safety from 8 to 32 weeks for all participants. Number of participants with any adverse event during the period.

Time frame:
8 to 32 weeks
Reported as:
Count of participants · Participants
Adverse Events During Reflux Esophagitis Maintenance Therapy
ParticipantsGroup 1Group 2
Adverse Events During Reflux Esophagitis Maintenance Therapy716
PrimaryAdverse Events During Gastric Ulcer or Duodenal Ulcer Recurrence Prevention Therapy

Prevention of gastric ulcer or duodenal ulcer recurrence associated with long term non-steroidal anti-inflammatory drugs or low-dose aspirin therapy study part: Safety from 0 to 32 weeks for all participants. Number of participants with any adverse event during the period.

Time frame:
0 to 32 weeks
Reported as:
Count of participants · Participants
Adverse Events During Gastric Ulcer or Duodenal Ulcer Recurrence Prevention Therapy
ParticipantsGroup 3Group 4
Adverse Events During Gastric Ulcer or Duodenal Ulcer Recurrence Prevention Therapy811
SecondaryAdverse Events During Reflux Esophagitis Maintenance Therapy

Maintenance therapy for healed reflux esophagitis study part: Safety from 8 to 52 weeks for participants who continued the study treatment after Week 32. Number of participants with any adverse event during the period

Time frame:
8 to 52 weeks
Reported as:
Count of participants · Participants
Adverse Events During Reflux Esophagitis Maintenance Therapy
ParticipantsGroup 1Group 2
Adverse Events During Reflux Esophagitis Maintenance Therapy615
SecondaryAdverse Events During Gastric Ulcer or Duodenal Ulcer Recurrence Prevention Therapy

Prevention of gastric ulcer or duodenal ulcer recurrence associated with long term non-steroidal anti-inflammatory drugs or low-dose aspirin therapy study part: Safety from 0 to 52 weeks for participants who continued the study treatment after Week 32. Number of participants with any adverse event

Time frame:
0 to 52 weeks
Reported as:
Count of participants · Participants
Adverse Events During Gastric Ulcer or Duodenal Ulcer Recurrence Prevention Therapy
ParticipantsGroup 3Group 4
Adverse Events During Gastric Ulcer or Duodenal Ulcer Recurrence Prevention Therapy66

Adverse events

Collected over Serious adverse events were collected from the date of signing of informed consent to 52 weeks or withdrawal. Other adverse events were collected from the start of investigational drug administration to 52 weeks or withdrawal.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 10/7 (0%)0/7 (0%)7/7 (100%)
Group 20/21 (0%)1/21 (4.8%)20/21 (95.2%)
Group 30/9 (0%)3/9 (33.3%)9/9 (100%)
Group 40/13 (0%)2/13 (15.4%)11/13 (84.6%)
Most frequent serious events
Most frequent serious events
EventGroup 1Group 2Group 3Group 4
Campylobacter gastroenteritisInfections and infestations0/71/211/90/13
Chronic recurrent multifocal osteomyelitisMusculoskeletal and connective tissue disorders0/70/211/90/13
Pulmonary artery atresiaCongenital, familial and genetic disorders0/70/211/90/13
Cyclic vomiting syndromeGastrointestinal disorders0/70/211/90/13
Otitis media acuteInfections and infestations0/70/210/91/13
Polyarteritis nodosaVascular disorders0/70/210/91/13
Skin ulcerSkin and subcutaneous tissue disorders0/70/210/91/13
Most frequent other events
Showing 10 of 95
Most frequent other events
EventGroup 1Group 2Group 3Group 4
NasopharyngitisInfections and infestations6/76/212/94/13
InfluenzaInfections and infestations3/72/210/93/13
PharyngitisInfections and infestations3/70/212/93/13
GastroenteritisInfections and infestations2/76/213/90/13
BronchitisInfections and infestations2/70/211/90/13
Thermal burnInjury, poisoning and procedural complications2/70/210/90/13
ConstipationGastrointestinal disorders1/75/211/90/13
VomitingGastrointestinal disorders1/72/212/91/13
PyrexiaGeneral disorders1/71/212/90/13
Streptococcal infectionInfections and infestations0/71/212/90/13

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Group 1Group 2Group 3Group 4Total
Mean3.7 ± 1.710.3 ± 2.25.2 ± 2.111.3 ± 2.48.7 ± 3.7
Age, Customized
Age, Customized(Participants)Group 1Group 2Group 3Group 4Total
<=3 years old40206
4 - 5 years old10304
6 - 7 years old22318
8 - 9 years old081110
10 - 11 years old04059
12 -14 years old070613
Sex: Female, Male
Sex: Female, Male(Participants)Group 1Group 2Group 3Group 4Total
Female065718
Male7154632
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1Group 2Group 3Group 4Total
American Indian or Alaska Native00000
Asian72191350
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White00000
More than one race00000
Unknown or Not Reported00000
08

Study locations

15 sites
  • Research Site
    Bunkyō City, 113-8431, Japan
  • Research Site
    Bunkyō City, 113-8519, Japan
  • Research Site
    Fuji-shi, 417-8567, Japan
  • Research Site
    Izumi-shi, 594-1101, Japan
  • Research Site
    Kagoshima, 890-8520, Japan
  • Research Site
    Kanazawa, 920-8641, Japan
  • Research Site
    Maebashi, 371-8511, Japan
  • Research Site
    Matsumoto-shi, 390-8621, Japan
  • Research Site
    Okayama, 701-1192, Japan
  • Research Site
    Sakaishi, 593-8304, Japan
  • Research Site
    Setagaya-ku, 157-8535, Japan
  • Research Site
    Shinjuku-ku, 160-0023, Japan
  • Research Site
    Takatsuki-shi, 569-8686, Japan
  • Research Site
    Yokohama, 230-8765, Japan
  • Research Site
    Yokohama, 232 8555, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Dec 2022, 53 months.

Results were first posted in Mar 2026, 3 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2018
First posted
Jun 12, 2018
StartActual
Jul 24, 2018
Primary completionActual
Dec 27, 2022
CompletionActual
Dec 27, 2022
Results first posted
Mar 4, 2026
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03553563
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 12, 2018
Start date
Jul 24, 2018
Primary completion
Dec 27, 2022
Completion
Dec 27, 2022
Results posted
Mar 4, 2026
Last update
Mar 4, 2026

Study contacts

Toshiaki Shimizu, M.D., Ph.D.
study chair · Juntendo University Graduate School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: D961H

Start the discussion